ABSTRACT
Immuno-cancer therapy is a growing field with a focus on highly personalized therapeutics that pharmaceutical companies, physicians, and patients have craved for a long time. The best way to introduce the most current development in the immunotherapy field might be to illustrate the competition between two giants in the pharmaceutical industry, Bristol-Myers Squibb (BMS) and Merck. While competition between Merck and BMS is good for the firms' success, more importantly, the main beneficiaries are cancer patients, who are eagerly waiting for the next promising and better therapeutic. Following the Kite Pharma case study and the firm's anticipated acquisition by Gilead Sciences, the chapter discusses the chimeric antigen receptor (CAR)-T cell treatments, their role in future therapeutics, and which companies have the capabilities to develop cancer treatments. Gross, Waksman, and Eshhar concluded that chimeric T-cell receptors with antitumor specificity will enable testing feasibility of CAR-T cell treatments in combating human tumors.
